PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
March 30, 2026European Journal of Paediatric Neurology0 citationsOpen Access

Cenobamate use for drug-resistant epilepsy in children: A real-world single-center study.

RWRonny WickströmMDMaria DahlinMÅMattias Åberg

Key Points

  • To evaluate the effectiveness and tolerability of cenobamate in children with drug-resistant epilepsy.
  • Single-center real-world study
  • Evaluated seizure reduction and side effects
  • Assessed treatment retention rates
  • Included preschool children as young as 3 years old
  • Cenobamate reduced seizures by over 50% in 60% of children
  • 12% of children became seizure-free
  • High treatment retention rate of 91% at 6 months
  • Cenobamate was effective across both focal and non-focal epilepsy types

Abstract

Highlights1. Cenobamate reduced seizures by >50% in 60% of children with drug-resistant epilepsy; 12% became seizure-free.2. Treatment was well tolerated; most side effects were mild, like fatigue or nausea.3. Retention rates were high; 91% at 6 months and 82% at 12 months of treatment.4. Cenobamate was as effective in preschool children from age 3 years and 15 kg body weight, as in older children. 5. Cenobamate was effective in focal as well as non-focal epilepsy types.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Wickström et al. (2026) studied this question.

synapsesocial.com/papers/69ca134b883daed6ee0952c2https://doi.org/10.1016/j.ejpn.2026.03.009
Ask AI
Helpful
Bookmark
Share
View Full Paper